Brief: Lumos Pharma Announces Clinical Updates
20/07/2021 21:26
July 20 (Reuters) - Lumos Pharma Inc LUMO.O :
* LUMOS PHARMA ANNOUNCES CLINICAL UPDATES
* LUMOS PHARMA INC - ORAGROWTH210 TRIAL IN PGHD PRIMARY
OUTCOME
6-MONTH DATA NOW ANTICIPATED IN 2H2023; TREATMENT PERIOD TO BE
EXTENDED TO 12 MONTHS
* LUMOS PHARMA INC - ORAGROWTH212 PK/PD TRIAL INITIATED IN
Q2
2021; TREATMENT PERIOD TO BE EXTENDED TO 12 MONTHS WITH PRIMARY
DATA AT 6-MONTHS
* LUMOS PHARMA INC - 6-MONTH PRIMARY OUTCOME DATA FOR
ORAGROWTH210
ARE NOW ANTICIPATED IN SECOND HALF OF 2023
Source text for Eikon: ID:nGNX9C6Vz4
Further company coverage: LUMO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Pharma
See all newsLumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
Lumos Pharma climbs on $38 mln go-private deal
Brief: Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures To Go Private Via A Tender Offer Of $4.25 Cash Per Share Plus Contingent Value Rights (Cvr)